CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion

San Diego – January 9, 2023 – Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team. The team also included Christophe Beauduin, Izzy Lubarsky, Ali Murata, Ajay Athavale, Megan Drill, Melissa Meza, Trey Reilly, Amy Hallman Rice, Matt Silverman, Howard Morse, Sharon Connaughton, Rubin Waranch, Natasha Leskovsek, Phil Mitchell, Charity Williams, MaryBeth Shreiner, Betsy Lewis, Mark Windfeld-Hansen, Patrick Sharma, Karen Tsai, Heidi Erlacher, Kristopher Kleiner and Amber Ausley Parlow. 

The upfront cash portion of the consideration represents a transaction value of approximately $1.3 billion, and the total consideration – including the contingent value right, if the milestone is achieved – will be approximately $1.8 billion.

Founded in 2018, CinCor has a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small-molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.